First in class lateral meniscus prothesis to relieve pain and restore mobility for KOA patientsbroad
AL U KNEED · Horizon Europe grant · 2023-04-01–2026-03-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
ATRO Medical developed a revolutionary prothesis that quickly relieves pain and restores mobility for severe KOA patients with a dysfunctional lateral meniscus: Trammpolin. We offer a minimally invasive, low impact procedure that postpones undesirable TKR and reduces KOA-related healthcare costs and medication dependency, while restoring full knee functioning. Our innovation is composed of a dual highly biocompatible polymer that carries the body weight and is uniquely shaped to reproduce the anatomical shape and mechanical properties of the native meniscus. The technology has proven itself for the medial meniscus and received the Breakthrough Device Designation of the US FDA in 2020. For successful market entry of our lateral Trammpolin in 2026, we aim to finalize our pre-clinical activities, conduct a FIH-study, and obtain CE-marking. In parallel we will perform a health economics analysis as a crucial step towards obtaining reimbursement for large scale uptake in the medical system.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| ATRO MEDICAL BV | NL | coordinator | €2,499,402 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.